Medicure Inc., a cardiovascular pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, and Barbados. The company primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non ST elevated acute coronary syndrome. The company's products also comprise PREXXARTAN, an oral solution used for the treatment of hypertension. In addition, it is developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications; and products for the treatment of acute cardiology. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-204-4877412
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$26.43 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/19/2019 (Estimated)
OptionableNot Optionable
Medicure (CVE:MPH) Frequently Asked Questions
What is Medicure's stock symbol?
Medicure trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MPH."
How were Medicure's earnings last quarter?
Medicure Inc. (CVE:MPH) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.04. The firm had revenue of $6.30 million for the quarter, compared to analyst estimates of $5.60 million. View Medicure's Earnings History.
When is Medicure's next earnings date?
Has Medicure been receiving favorable news coverage?
News articles about MPH stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medicure earned a news impact score of 0.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Medicure.
Who are some of Medicure's key competitors?
Some companies that are related to Medicure include Silence Therapeutics (SLN), Botanix Pharmaceuticals (BOT), Acasti Pharma (ACST), Enochian Biosciences (ENOB), Exicure (XCUR), IMV (IMV), Bioventix (BVXP), Arix Bioscience (ARIX), CorMedix (CRMD), Senesco Technologies (ELOX), Ergomed (ERGO), Ampliphi Biosciences (APHB), BioTime (BTX), CorMedix (CRMD) and MediGene (MDG1).
What other stocks do shareholders of Medicure own?
Who are Medicure's key executives?
Medicure's management team includes the folowing people:
- Dr. Albert David Friesen, Founder, Chairman, CEO & Pres (Age 72)
- Mr. James F. Kinley, CFO & Sec. (Age 41)
How do I buy shares of Medicure?
Shares of MPH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Medicure's stock price today?
One share of MPH stock can currently be purchased for approximately C$4.00.
How big of a company is Medicure?
What is Medicure's official website?
How can I contact Medicure?
Medicure's mailing address is 1250 Waverley St Suite 2, WINNIPEG, MB R3T 6C6, Canada. The company can be reached via phone at +1-204-4877412.
MarketBeat Community Rating for Medicure (CVE MPH)
MarketBeat's community ratings are surveys of what our community members think about Medicure and other stocks. Vote "Outperform" if you believe MPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
